ATRX and neuroblastoma: A previous study revealed that MYCN upregulates EZH2, leading to the inactivation of a tumor suppressor program in neuroblastoma [18]; meanwhile ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition [19].